Thumbnail Image
Publication

Effects of ascorbic acid, dehydroascorbic acid and methotrexate on breast cancer cell viability.

Dosunmu, Yewande
; 
Owusu-Apenten, Richard K.
Advisors
Editors
Other Contributors
Affiliation
University of Chester, University of Ulster
EPub Date
Publication Date
2017-10-28
Submitted Date
Collections
Clinical Sciences and Nutrition
Show all metadata
Files
Thumbnail Image
Main article
Adobe PDF, 1020.37 KB
Other Titles
Abstract
Aims: To examine the effects of ascorbic acid (AA), dehydroascorbic acid (DHA) and methotrexate (MTX) combined treatments on (MDA-MB-231) breast cancer cell viability and intracellular reactive oxygen species (ROS). Study Design: In-vitro method. Place and Duration of Study: Biomedical Sciences Research Institute, University of Ulster, Coleraine, BT52 1SA, United Kingdom. September 2016-2017 Methodology: Cytotoxicity tests were performed with MTX (0.01- 1000 µmol/l) alone or in combination with AA or DHA, for 72 h. Cell viability was measured by 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) or Sulforhodamine B (SRB) assays. Intracellular ROS was measured by 2’,7’-dichlorofluroscein diacetate assay. Results: Treatments of MDA-MB231 cells with single agents, showed dose dependent response with 50% inhibition of cell viability (IC50) of 110.5-201.4 µmol/l (MTX), 2237-5703 µmol/l (AA) or 2474 µmol/l (DHA). Combination studies showed clear synergisms for MTX (~10 µmol/l) and DHA or AA (1100 µmol/l) but weak or no interactions at other concentrations. Three days combination treatment of DHA showed decrease of ROS, which was reversed by MTX (>10 µmol/l). Conclusions: Co-treatment of methotrexate with AA or DHA showed synergism (C1<1.0) and enhanced cytotoxicity of the anti-folate towards MDA-MB-231 breast cancer cells. Intracellular ROS decreased with AA and DHA treatment, which might be useful for reducing MTX-related oxidative stress.
Citation
Dosunmu, Y. & Owusu-Apenten, R. (2017). Effects of Ascorbic Acid, Dehydroascorbic Acid and Methotrexate on Breast Cancer Cell Viability. Journal of Applied Life Sciences International, 14 (2),
Publisher
SCIENCEDOMAIN International
Journal
Journal of Applied Life Sciences International
Research Unit
URI
http://hdl.handle.net/10034/621939
DOI
10.9734/JALSI/2017/37185
PubMed ID
PubMed Central ID
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
2394-1103
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
Additional Links
http://www.sciencedomain.org/abstract/21618